Source: OncLive, June 2025
Key Takeaways
- Lifileucel therapy achieved a 31.4% objective response rate in advanced melanoma patients, with 5.9% complete responses and 25.5% partial responses.
- The median duration of response was 36.5 months, with 31.3% of responders maintaining responses at 5 years.
One-time lifileucel (Amtagvi), a tumor-infiltrating lymphocyte cell therapy, generated durable responses and favorable 5-year overall survival (OS) outcomes in patients with pretreated, advanced melanoma, according to the final analysis of the phase 2 C-144-01 study (NCT02360579) presented at the 2025 ASCO Annual Meeting.1